Advertisement

Topics

Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models

08:56 EDT 17 Apr 2019 | SCRIP

Roche CEO Severin Schwan says the process of paying for hugely expensive gene therapies that can cure diseases needs revamping.

      

Related Stories

 

Original Article: Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models

NEXT ARTICLE

More From BioPortfolio on "Roche CEO: Novel But Costly Gene Therapies Justify New Payment Models"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...